A Phase 3 Study of VVN461 Ophthalmic Solution for Noninfectious Anterior Uveitis (NCT07136805) | Clinical Trial Compass
Not Yet RecruitingPhase 3
A Phase 3 Study of VVN461 Ophthalmic Solution for Noninfectious Anterior Uveitis
152 participantsStarted 2025-10-01
Plain-language summary
This is a multicenter, randomized, single-masked, active-controlled, parallel, Phase III pivotal study in China
Who can participate
Age range18 Years – 70 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* At the time of signing the informed consent form (ICF), the subject must be aged 18 to 70 years (inclusive);
* At screening, the affected eye is diagnosed with non-infectious anterior uveitis (acute or recurrent acute, only unilateral eye affected patients are included);
* At screening, the ACC grade of the affected eye is 2+ or 3+ \[SUN criteria\];
* At screening, the ACF grade of the affected eye is ≥1 \[SUN criteria\];
Exclusion Criteria:
* At screening, the affected eye has an ACC grade of 4+ or hypopyon
* Diagnosis of intermediate uveitis, posterior uveitis, or panuveitis in either eye at the time of screening
What they're measuring
1
Change from baseline in anterior chamber cell (ACC) grade in the study eye at Day 14